Purpose of the development: Combined therapy of dyslipidemia, normalization of lipid profile, the prevention of atherosclerosis in clinical and rehabilitative medicine.

Recommended application field: Biochemical Company.

Advantages over analogues: With hyperlipemia Aterobtor reduces low-density lipoprotein (LDL), total cholesterol (TC), triglyceride (TG), non-high-density lipoprotein (non-HDL), apolipoprotein B (apoB), the ratio of TC / HDL, apoB / apoA increases high-density lipoprotein (HDL). Antiatherogenic effect of Aterobior determined by its ability to significantly reduce the rate of accumulation of oxidized low-density lipoproeinov (okLNP) in cell cultures of human aortic and prevent apoptosis, reduced levels of metalloproteins and the expression of myosin in smooth vessels, thus reducing their biosynthetic activity.

The development stage readiness: tested in laboratory condition

Description of the development:
()
Capsules cylindrical, with rounded edges and smooth opaque surface. Color of the capsule and covers - white, light green or dark green, and / or - the red and white. The contents of the capsule: hygroscopic powder white or pale yellowish, almost odorless. Pharmacological properties. Aterobior - a complex biological product derived from the biomass of cyanobacteria Spirulina platensis. Contains three active ingredients: extract of immunoactive amino acids (valine, tryptophan, threonine, aspartic acid, glutam acid, alanine, arginine, cysteine??, glycine, serine, gamma-aminobutyric acid) sulfated poly saccharides and phospholipids - phosphatidylinositol and of Phosphatidylinositol Colin.

Possibility of transfer abroad:
Licence's sale
Combinated reduction to industrial level

Photo

Country Moldova

For additional information turn to:
E-mail: gal@uintei.kiev.ua